Innoviva (INVA) Cash from Investing Activities (2010 - 2026)
Innoviva (INVA) posted Cash from Investing Activities of $37.0 million for Q1 2026, up 119.5% on a QoQ basis from $16.9 million in Q3 2025, and up 206.73% year-over-year from $12.1 million in Q1 2025.
Innoviva (INVA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Innoviva's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $37.0 million for Q1 2026.
- Quarterly Cash from Investing Activities rose 206.73% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.3 million (up 141.51% YoY) and the FY2025 annual result came in at $40.5 million, up 163.49% from the prior year.
- Cash from Investing Activities was $37.0 million for Q1 2026 at Innoviva, up from $16.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $37.0 million in Q1 2026 and bottomed at -$143.2 million in Q1 2022.
- A 5-year average of -$30.0 million and a median of -$35.7 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 442.38% — and 2026, when it soared 206.73%.
- Innoviva's Cash from Investing Activities stood at -$48.0 million in 2022, then decreased by 28.47% to -$61.6 million in 2023, then advanced by 21.59% to -$48.3 million in 2024, then soared by 134.9% to $16.9 million in 2025, then soared by 119.5% to $37.0 million in 2026.
- Business Quant data shows INVA's Cash from Investing Activities at $37.0 million in Q1 2026, $16.9 million in Q3 2025, and $33.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | 37.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.01 Mn |
| Mar 31, 2026 | 37.01 Mn |
| Sep 30, 2025 | 16.86 Mn |
| Sep 30, 2025 | 16.86 Mn |
| Jun 30, 2025 | 33.12 Mn |
| Jun 30, 2025 | 33.12 Mn |
| Mar 31, 2025 | -34.67 Mn |
| Mar 31, 2025 | -34.67 Mn |
| Sep 30, 2024 | -48.31 Mn |
| Sep 30, 2024 | -48.31 Mn |
| Mar 31, 2024 | -43.04 Mn |
| Mar 31, 2024 | -43.04 Mn |
| Sep 30, 2023 | -61.61 Mn |
| Sep 30, 2023 | -61.61 Mn |
| Mar 31, 2023 | -35.72 Mn |
| Mar 31, 2023 | -35.72 Mn |
| Sep 30, 2022 | -47.96 Mn |
| Sep 30, 2022 | -47.96 Mn |
| Jun 30, 2022 | -2.52 Mn |
| Jun 30, 2022 | -2.52 Mn |